Skip to main content
OpenTrials
Completed

NCT Number: NCT02726776

Suspension Syndrome

Suspension syndrome refers to a potentially life-threatening condition that can occur in unconscious persons after prolonged suspension in a harness. To date, our understanding of the pathophysiology and appropriate treatment is based primarily on case reports and expert opinion. The main pathophysiological hypothesis implicates blood pooling in the lower extremity and lack of return via muscle pumping. However, a recent French study could not support this hypothesis. Other mechanisms, such as a central vagal reflex may play a role in the pathophysiology of suspension syndrome. The aim of this study is to better understand the pathophysiological basis of suspension syndrome and to develop practical recommendations for prevention and treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Circulatory Collapse Autonomic Nervous System Diseases Cardiovascular Diseases Circulatory Failure Consciousness Disorders Hypotension Hypotension, Orthostatic Nervous System Diseases Neurobehavioral Manifestations Neurologic Manifestations Orthostatic Hypotension Orthostatic Intolerance Pathologic Processes Pathological Conditions, Signs and Symptoms Primary Dysautonomias Shock Signs and Symptoms Syncope Syncope, Vasovagal Syncope, Vasovagal, Neurally-Mediated Unconsciousness Vascular Diseases

Age range

18 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers
  • Age 18-50 years
  • ASA class 1
  • Signed informed consent

Exclusion criteria

  • Age <18 or >50 years
  • ASA class >1
  • Informed consent not signed

Treatment and study plan

Suspension in a harness

Other

Climbing

Other

Primary outcomes

  1. Heart rate

    Time frame: Change from baseline (measurement at minute 0) -> suspension phase (minute 10, timepoint immediately before interruption of suspension phase [max 60 minutes]) -> minute 5 and minute 15 after suspension phase

  2. Blood pressure

    Time frame: Change from baseline (measurement at minute 0) -> suspension phase (minute 10, timepoint immediately before interruption of suspension phase [max 60 minutes]) -> minute 5 and minute 15 after suspension phase

Secondary outcomes

  1. Change in maximal Diameter of superficial femoral vein

    Time frame: Change from baseline (measurement at minute 0) -> suspension phase (minute 10, timepoint immediately before interruption of suspension phase [max 60 minutes]) -> minute 5 and minute 15 after suspension phase

    Ultrasound measurement of the Diameter of the superficial femoral vein in millimeters

  2. Change in interbeat-interval

    Time frame: Change from baseline (measurement at minute 0) -> suspension phase (minute 10, timepoint immediately before interruption of suspension phase [max 60 minutes]) -> minute 5 and minute 15 after suspension phase

    electrocardiographic measurement of interbeat interval in milliseconds (ms)

Sponsors and collaborators

Lead sponsor

Institute of Mountain Emergency Medicine

Other

Registry information

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Apr 4, 2016
Registry last updated
Apr 6, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.